SCHEMBL415254

SCHEMBL415254

Oc1ccc(-c2nc3cc(-c4ccc5[nH]c(-c6ccc(O)cc6)nc5c4)ccc3[nH]2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.55
PRKD3 O94806 1/20 0.55
PAK4 O96013 1/20 0.55
PDGFRA P16234 1/20 0.55
LTK P29376 1/20 0.55
MAP2K2 P36507 1/20 0.55
MAPK8 P45983 1/20 0.55
CDK8 P49336 1/20 0.55
RPS6KA3 P51812 1/20 0.55
PRKX P51817 1/20 0.55
NEK2 P51955 1/20 0.55
LIMK1 P53667 1/20 0.55
CDK5 Q00535 1/20 0.55
PRKCQ Q04759 1/20 0.55
MAP4K2 Q12851 1/20 0.55
ROCK1 Q13464 1/20 0.55
LRRK2 Q5S007 1/20 0.55
TAOK1 Q7L7X3 1/20 0.55
AURKB Q96GD4 1/20 0.55
CLK4 Q9HAZ1 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5579984 0.93 CHEK1 (0.59) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL16498509 0.92 KDM4E (0.57) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL14669317 0.89 NPC1 (0.62) GUSBGAATNKSPARP1TNKS2
SCHEMBL27873811 0.86 MEN1 (0.63) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL7388566 0.86 GUSB (0.57) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL7394693 0.86 KDM4E (0.54) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL31289511 0.86 MEN1 (0.63) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL27236921 0.86 MMP2 (0.55) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL7248166 0.85 CHEK1 (0.69) CHEK1PRKD3PAK4PDGFRALTK
SCHEMBL9306624 0.85 HPSE (0.52) CHEK1PRKD3PAK4PDGFRALTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975416-B2 Antibacterial compounds SUMMIT CORPORATION PLC (GB) 2015-03-10 US claimed
EP-2373631-B1 ANTIBACTERIAL COMPOUNDS SUMMIT CORP PLC (GB) 2015-02-25 EP claimed
US-10961202-B2 Bis-benzimidazole compounds and methods of using the same THE SCRIPPS RESEARCH INSTITUTE (US) 2021-03-30 US disclosed
US-10961202-B2 Bis-benzimidazole compounds and methods of using the same THE SCRIPPS RESEARCH INSTITUTE (US) 2021-03-30 US disclosed
US-20190152924-A1 BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2019-05-23 US disclosed
US-20190152924-A1 BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2019-05-23 US disclosed
US-9763925-B2 Antibacterial compounds SUMMIT THERAPEUTICS PLC (GB) 2017-09-19 US disclosed
EP-3095783-A1 ANTIBACTERIAL COMPOUNDS Summit Corporation Plc (GB) 2016-11-23 EP disclosed
US-20160184283-A1 ANTIBACTERIAL COMPOUNDS SUMMIT (OXFORD) LIMITED (GB) 2016-06-30 US disclosed
US-9314456-B2 Antibacterial compounds SUMMIT THERAPEUTICS PLC (GB) 2016-04-19 US disclosed
EP-2907813-A1 Antibacterial Compound Summit Corporation Plc (GB) 2015-08-19 EP disclosed
US-20150150861-A1 ANTIBACTERIAL COMPOUNDS SUMMIT (OXFORD) LIMITED (GB) 2015-06-04 US disclosed
US-8975416-B2 Antibacterial compounds SUMMIT CORPORATION PLC (GB) 2015-03-10 US disclosed
EP-2373631-B1 ANTIBACTERIAL COMPOUNDS SUMMIT CORP PLC (GB) 2015-02-25 EP disclosed
US-20120020950-A1 ANTIBACTERIAL COMPOUNDS SUMMIT CORPORATION PLC 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10961202-B2 Bis-benzimidazole compounds and methods of using the same HNRNPH1, HNRNPH3, HNRNPUL2 CHEK1 1378/4885PRKD3 3267/4885PAK4 3791/4885
US-20160184283-A1 ANTIBACTERIAL COMPOUNDS MRPL21, RPN2, ALPI CHEK1 3669/4885PRKD3 4215/4885PAK4 1679/4885
US-20190152924-A1 BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME HNRNPH1, HNRNPH3, HNRNPUL2 CHEK1 1378/4885PRKD3 3267/4885PAK4 3791/4885
US-20120020950-A1 ANTIBACTERIAL COMPOUNDS RPN2, MRPL21, ALPI CHEK1 3667/4885PRKD3 4212/4885PAK4 1721/4885
US-20150150861-A1 ANTIBACTERIAL COMPOUNDS MRPL21, RPN2, ALPI CHEK1 3669/4885PRKD3 4215/4885PAK4 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.